



Resveratrol Protects the Prefrontal Cortex Against Methamphetamine Neurotoxicity: Association with SIRT1 and Changes in miR-22, miR-9, and miR-138 Expression

Seyed Khalil Rashidi ^{1,2}, Mitra Ansari Dezfouli ^{3,*}, Dian Dayer ¹, Farzaneh Saeidi ⁴

¹ Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

² Department of Medical Biotechnology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³ Hearing Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁴ Department of Medical Genetics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

*Corresponding Author: Hearing Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: mitraansari84@gmail.com

Received: 8 March, 2026; Revised: 18 April, 2026; Accepted: 11 May, 2026

Abstract

Background: Methamphetamine (METH) is a well-known psychostimulant that induces neurotoxicity and cognitive decline. Resveratrol is a natural phenolic compound found in grapes and berries. Sirtuin-1 (SIRT1) is an important protein involved in neuroprotective pathways. Several microRNAs are dysregulated following METH use, which can affect gene expression.

Objectives: This study evaluated the contribution of SIRT1 and its associated microRNAs to resveratrol-mediated neuroprotection against METH-induced neurotoxicity, cognitive decline, and neuronal damage in the prefrontal cortex (PFC).

Methods: Rats received METH (5 mg/kg) for 14 days. Resveratrol was administered orally before METH injection. Object-based attention and Y-maze tests were performed to assess attention and working memory, respectively. SIRT1 gene expression and protein levels were assessed using quantitative PCR and immunoblotting. miRNAs related to SIRT1 were predicted, and changes in their levels were examined. Morphological changes in PFC tissue were evaluated using histological analysis.

Results: Chronic METH use induced PFC damage and impaired attention and working memory. It also decreased SIRT1 levels and upregulated miR-22 - 3p, miR-9 - 5p, miR-138 - 5p, and miR-133a-3p in the PFC. Administration of resveratrol prevented METH-induced PFC damage and improved cognition. Resveratrol treatment reduced levels of miR-22 - 3p, miR-9 - 5p, and miR-138 - 5p, accompanied by increased SIRT1 levels.

Conclusions: Resveratrol treatment exerted protective effects in the PFC against METH toxicity. These effects were associated with increased SIRT1 and altered expression of several SIRT1-related microRNAs, including miR-22 - 3p, miR-9 - 5p, and miR-138 - 5p. However, further research is needed to clarify the roles of SIRT1 and associated microRNAs in resveratrol-mediated neuroprotection.

Keywords: Methamphetamine, Resveratrol, Sirtuin 1, Working Memory, Attention

1. Background

Methamphetamine (METH) is a potent psychostimulant that poses major public health and legal challenges. METH can cross the blood-brain barrier because of its small molecular size and lipid solubility. METH induces oxidative stress and neuronal damage in the central nervous system. Moreover, brain structural findings have shown long-term structural alterations in

different cortical regions in METH abusers (1). The prefrontal cortex (PFC) is crucially involved in working memory, attention, and cognitive regulation of behavior. In addition, the PFC contributes to inhibiting risky decisions, such as those related to drug craving; however, this function is reduced in drug-dependent patients (2). A significant decrease in gray matter density in the PFC of METH addicts has been reported and was associated with poor executive function in

Copyright © 2026, Rashidi et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Rashidi SK, Ansari Dezfouli M, Dayer D, Saeidi F. Resveratrol Protects the Prefrontal Cortex Against Methamphetamine Neurotoxicity: Association with SIRT1 and Changes in miR-22, miR-9, and miR-138 Expression. Jundishapur J Nat Pharm Prod. 2026;21(2):e171761. doi: <https://doi.org/10.5812/jjnpp-171761>

these patients. METH addiction has also been associated with decreased performance in cognition, attention, motivational behaviors, decision-making, memory, and verbal recognition (3).

Resveratrol is a natural phenolic compound found in several common foods, especially grapes and blueberries. Resveratrol has several neuroprotective properties (4, 5). Administration of resveratrol protects neurons against morphological damage and oxidative stress. Moreover, resveratrol inhibits apoptosis in PFC neurons and increases BDNF levels in this area, thereby improving cognitive memory in a mouse model of Alzheimer disease (6). The biological functions of resveratrol are attributed to its antioxidative and anti-inflammatory effects, as well as increased mitochondrial biogenesis (4, 7).

Sirtuin-1 (SIRT1) protein is a crucial intracellular deacetylase involved in antioxidant protection and mitochondrial biogenesis. SIRT1 regulates epigenetic mechanisms to control the transcription of proteins involved in cellular metabolism (8). SIRT1 also influences various cellular processes related to DNA damage and oxidative stress (5, 9). SIRT1 is abundantly expressed in the brain, especially in the PFC and hippocampal regions (10). Downregulation of SIRT1 in the PFC results in increased neuronal damage and oxidative stress and decreased working memory and attention (10).

MicroRNAs (miRNAs) are short noncoding RNAs containing 19 - 24 nucleotides that play crucial roles in the regulation of gene expression (11). Notably, each miRNA has the potential to target many mRNAs, whereas a single mRNA can be targeted by multiple miRNAs, indicating that miRNAs are involved in diverse biological pathways. The transcription levels of several miRNAs are altered following METH use, which could affect the levels of various crucial genes and induce METH neurotoxicity (11).

2. Objectives

This study evaluated the effects of resveratrol on PFC tissue in a rat model of chronic METH use. In addition, we investigated SIRT1 alterations in METH-induced neurotoxicity and in the protective mechanisms of resveratrol. Predicted miRNAs targeting SIRT1 were evaluated following METH toxicity and resveratrol treatment. We also examined the deleterious effects of METH on attention and working memory, two cognitive domains related to the PFC, and assessed the modulation of these effects by resveratrol administration. Morphological changes in PFC neurons following METH and resveratrol treatment were also evaluated.

3. Methods

3.1. Animals and Drugs

Thirty-two male Wistar rats (200 ± 30 g) from the Pasteur Institute were housed at $20 - 22^{\circ}\text{C}$ and 50% - 70% humidity under a 12-hour light cycle, with ad libitum access to food and water. Before the procedures, the animals underwent a 1-week habituation period. Animals were randomized to treatment groups using block randomization (4 animals per block). Exclusion criteria were illness, movement disorder, or weight loss of more than 20% of the initial weight. No animals were excluded; all completed the experiment, and no deaths, morbidity, or weight loss greater than 20% were observed during the study period. METH was diluted in normal saline and administered subcutaneously at 5 mg/kg in a volume of 1 mL/kg (200 mL for a rat weighing 200 g). Resveratrol (Sigma-Aldrich) was dissolved in 0.5% (w/v) carboxymethyl cellulose (vehicle) and administered at a final dose of 25 mg/kg in a volume of 1 mL/kg. Animals received 5 mg/kg METH or saline once daily between 8:30 and 9 AM. Resveratrol 25 mg/kg or vehicle was administered by oral gavage 30 minutes before the injection (Figure 1). The METH dose was selected based on previous studies showing cognitive impairment without motor dysfunction (10, 12). The resveratrol dose was selected based on previous studies demonstrating protective effects on memory and learning (13, 14). To minimize bias, researchers involved in behavioral, molecular, and histological tests were fully blinded to group assignment during evaluations. Data analysis was performed by another researcher who was unaware of group allocation. Group sizes were determined based on previous studies indicating that $n = 8$ provided sufficient power to detect the effects of drug treatments (10, 15). To avoid variability due to the estrous cycle and hormonal fluctuations in behavioral and gene-expression assessments (16), experiments were conducted in males. The experiment was performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the ethical guidelines of the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, with ethical code IR.AJUMS.AEC.1404.061.

3.2. Working Memory Test

The Y-maze apparatus was made of plexiglass and consisted of 3 arms measuring 15 cm (width) $\times$ 30 cm (height) $\times$ 40 cm (length). Each rat was placed at the end of one arm with access to the apparatus. The order of arm entries was recorded for 8 minutes. An arm entry




Figure 1. Treatment timeline and details of experimental processes. Timeline of treatments, behavioral tests, and tissue collection (A). Before starting the procedures, rats underwent a 1-week acclimation period. The animals were randomly divided into 4 groups ($n = 8$ per group). Animal treatment was performed for 14 consecutive days (B). METH was diluted in normal saline and administered subcutaneously at a dose of 5 mg/kg in a volume of 1 mL/kg. Resveratrol was dissolved in 0.5% carboxymethylcellulose (vehicle) at a dose of 25 mg/kg in a volume of 1 mL/kg. Treatment continued for 14 days. Behavioral tests were performed on days 15 and 16. Then, PFC tissue was removed from 6 animals per group for molecular studies, while the brains of 2 animals per group were fixed for histological studies. Abbreviations: METH, methamphetamine; CMC, carboxymethyl cellulose; Veh, vehicle.

was recorded when all 4 paws entered an arm. Spontaneous alternation behavior was defined as consecutive successful entries into all arms within a set of 3 arm entries. The total number of arm entries was used as an index of locomotor function.

3.3. Attention Test

The object-based attention apparatus consisted of an opaque plexiglass box containing 2 chambers: an exploration room (60 cm × 40 cm × 50 cm) and a test room (30 cm × 40 cm × 50 cm). One day before testing, rats were habituated to the apparatus by allowing free exploration of both chambers for 10 minutes. During the acquisition phase, the animal was placed in the exploration room for 5 minutes, where five different objects of the same color were positioned. The exploration duration for each object was recorded. The animals were then immediately moved to the side chamber (test room) for the retention phase. During retention, a previous object was placed in a location analogous to its earlier position, and a new object of a similar color was added parallel to the previous objects. During retention, the animal explored both objects for 5 minutes (Figure 2A). Recognition was calculated as $(T_{\text{new obj}} \times 100) / (T_{\text{previous obj}} + T_{\text{new obj}})$, where T

previous obj and $T_{\text{new obj}}$ represent the time spent on the previous and new objects, respectively.

3.4. Real-time PCR Analysis

After treatment, PFC tissues were isolated and stored in a nitrogen tank. Total cDNA was synthesized and used to measure expression changes across groups. For quantitative miRNA-targeting PCR, stem-loop primers were used at 37°C for 65 minutes and 95°C for 8 minutes. For accurate normalization and quantification, U6 snRNA was used as the endogenous control for miRNA levels, whereas GAPDH was used as the control gene to assess SIRT1 gene expression. Relative expression was analyzed using the $2^{-\Delta\Delta Ct}$ method. Owing to the low variation in molecular values among animals within each group and the need to fix brains from 2 animals for histological analysis, $n = 6$ animals per group were used for molecular testing. The primers are listed in Table 1.

3.5. Bioinformatics Analysis

miRNAs putatively targeting the SIRT1 gene were identified using a comprehensive prediction approach with TargetScan software (www.targetscan.org). MicroRNAs with a higher probability of preferential




Figure 2. Assessment of attention by object-based attention test and working memory using the Y-maze. Schematic procedure of the object-based attention test (A). Evaluation of the recognition index in different groups (B). The duration of animal exploration for each object during the acquisition phase is indicated as exploration time (C). The effect of METH injection and resveratrol administration on alternation behavior (D) and total arm entries (E) during the Y-maze test are presented. **** $P < 0.0001$ compared with the Saline + Veh group; ### $P < 0.001$ and #### $P < 0.0001$ compared with the METH + Veh group; $n = 8$ in each group.

conservation were selected for further analysis. These interactions were predicted bioinformatically in this study. After identifying the predicted miRNAs, their sequences were retrieved from miRDB (www.mirdb.org)

for further analysis and experimental validation. MicroRNA primers were designed using stem-loop RT primers (www.srnprimerdb.com).

Table 1. Primer Sequences^a

Sequence	Primer	Genes
5'-ATACCTGGAGCAGGTTCAG-3'	F	SIRT1
5'-TGTCATACTTCATGGCTCTATG-3'	R	SIRT1
5'-TGTGACAAAGTGGACATTGTG-3'	F	GAPDH
5'-TCCTGGAAGATGGTGATGGG-3'	R	GAPDH
5'-AACAGTGAAGCTGCCAGTTG-3'	F	miR-22 - 3p
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGACAGCTT-3'	Loop	miR-22 - 3p
5'-AAGCGCCTTCTTGGTTATCTAG-3'	F	miR-9 - 5p
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGACTATAC-3'	Loop	miR-9 - 5p
5'-ACAAGAGCTGGTGTGTGAA-3'	F	miR-138 - 5p
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGACCGGCT-3'	Loop	miR-138 - 5p
5'-AACAGTGTTGGTCCCTTCA-3'	F	miR-133a-3p
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGACCACTG-3'	Loop	miR-133a-3p
5'-GTCGTATCCAGTGCAGGGT-3'	R	miR-General
5'-GTGCTGGCATGGCAGTACA-3'	F	U6
5'-TTAAACATGGAACGCCTCATGAT-3'	R	U6

^a Abbreviations: SIRT1, sirtuin-1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.




Figure 3. Effect of METH and resveratrol on SIRT1 mRNA and protein levels in the PFC. qRT-PCR analysis revealed that SIRT1 mRNA levels in the PFC were decreased in the METH + Veh group. Conversely, resveratrol administration enhanced SIRT1 mRNA levels in the METH + Resveratrol group (A). Representative western blotting for SIRT1 and β-actin in different groups (B). Western blot analysis showed a reduction in SIRT1 protein levels in the PFC in the METH + Veh group. However, SIRT1 protein levels increased in the METH + Resveratrol group (C). **** $P < 0.0001$ compared with the Saline + Veh group; #### $P < 0.0001$ compared with the METH + Veh group; $n = 6$ in each group.

3.6. Immunoblotting Analysis

PFC tissues were lysed in lysis buffer, and protein concentration was determined using the Bradford method. Samples were separated on a 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred to a PVDF membrane. Membranes were blocked with 2% skim milk to prevent nonspecific binding and then incubated with primary antibodies. After washing, membranes were incubated with a

horseradish peroxidase-conjugated secondary antibody. ECL reagents were used for detection, and X-ray films were used to visualize the bands. Immunoreactive blots were normalized to β-actin in each group. Band intensity was quantified using ImageJ.

3.7. Histological Analysis

Fixed brain tissues were processed for paraffin embedding. Blocks were sectioned at 5 - 7 μm using a sliding microtome (Leitz 1512, Italy). Slides were

deparaffinized, hydrated, and washed with PBS. Sections were stained with cresyl violet and assessed using a light microscope (Motic, China). The histopathologist who performed the histological interpretation was blinded to the experimental groups. To reduce observer bias, all stained slides were independently evaluated by 2 experienced observers; in cases of disagreement, another senior expert supervised the work. All 3 observers were blinded to grouping. This multi-observer approach, conducted by blinded analysts, was used to ensure the validity of the histological findings. Stained sections were examined under a light microscope with blinding to grouping. For each animal, 3 nonoverlapping fields of the PFC were imaged (total, 6 slides). The numbers of morphologically intact and damaged neurons were counted manually using ImageJ software. Neuronal density was calculated as the number of intact neurons per field of view. In addition, the number of damaged neurons per field was calculated.

3.8. Statistical Analysis

All data were analyzed using GraphPad Prism 8 and are presented as mean $\pm$ SEM. One-way analysis of variance (ANOVA) was used to compare groups, followed by the Tukey post hoc test. Before one-way ANOVA, normality and homogeneity of variance were assessed using the Shapiro-Wilk test and the Levene test, respectively. All data sets met the assumptions required for parametric testing. No statistical outliers were excluded from the analysis. Animal exclusion was based only on predefined experimental criteria (illness, movement disorder, or weight loss greater than 20%) before statistical analysis. Effect sizes were calculated as η^2 for ANOVA analyses. The significance level was set at $P < 0.05$. A post hoc power analysis was performed using G*Power version 3.1 for one-way ANOVA (fixed effects, omnibus test). The analysis was based on 4 groups, $n = 6$ for the molecular study, a total sample size of 24, and an α level of 0.05. Effect sizes (Cohen f) were calculated from eta-squared (η^2) values using the formula:

$$f = \sqrt{\left(\frac{\eta^2}{1 - \eta^2}\right)}$$

The statistical power for all molecular outcomes was very high (approximately > 0.95), based on the calculated effect sizes.

4. Results

4.1. Effect of METH and Resveratrol on Object-Based Attention

Exploration duration did not differ significantly among groups ($F(3, 28) = 0.38$, $P = 0.75$). However, significant between-group differences were observed in the recognition index during the acquisition phase ($F(3, 28) = 21.21$, $P < 0.0001$, $\eta^2 = 0.56$). Animals in the METH + Veh group explored the new object less than those in the Saline + Veh group (37.25 ± 2.46 vs 60.63 ± 3.29 , $P < 0.0001$), indicating impaired object-based attention in METH-injected animals. Furthermore, the recognition index improved in animals receiving resveratrol before METH injection compared with that in the METH + Veh group (57.50 ± 3.01 vs 37.25 ± 2.46 , $P < 0.001$). These results indicate that oral administration of resveratrol ameliorated METH-induced attention deficits in rats (Figure 2B and C).

4.2. Effect of METH and Resveratrol on Working Memory

As shown in Figure 2D, significant between-group differences were observed in spontaneous alternation behavior ($F(3, 28) = 67.88$, $P < 0.0001$, $\eta^2 = 0.88$). The percentage of spontaneous alternation behavior was reduced in the METH + Veh group compared with the Saline + Veh group (0.35 ± 0.02 vs 0.80 ± 0.02 , $P < 0.0001$). Moreover, the percentage of spontaneous alternation behavior increased with resveratrol administration in the METH + Resveratrol group compared with the METH + Veh group (0.74 ± 0.02 vs 0.35 ± 0.02 , $P < 0.0001$).

There was no difference in the total number of arm entries, indicating that locomotion was not affected in the Y-maze ($F(3, 28) = 1.84$, $P = 0.16$) (Figure 2E).

4.3. Effect of METH and Resveratrol on SIRT1 Levels in the PFC

The data showed that SIRT1 mRNA expression differed among groups ($F(3, 20) = 43.75$, $P < 0.0001$, $\eta^2 = 0.86$). SIRT1 mRNA expression decreased in the METH + Veh group compared with the control group (0.48 ± 0.04 vs 1.05 ± 0.05 , $P < 0.0001$). As presented in Figure 3A, SIRT1 mRNA expression in the METH + Resveratrol group increased compared with that in the METH + Veh group (0.94 ± 0.03 vs 0.48 ± 0.04 , $P < 0.0001$).

Western blot analysis showed differences among the treated groups ($F(3, 20) = 62.32$, $P < 0.0001$, $\eta^2 = 0.90$). The data indicated a marked reduction in SIRT1 protein levels in the METH-treated group compared with the control group (0.47 ± 0.03 vs 1.06 ± 0.04 , $P < 0.0001$). Conversely, SIRT1 protein levels were higher in the METH + Resveratrol group than in the METH + Veh group (0.87

± 0.02 vs 0.47 ± 0.03 , $P < 0.0001$). These findings indicate a potential inhibitory effect of resveratrol on METH-induced SIRT1 reduction (Figure 3B and C).

4.4. Effect of METH and Resveratrol on Predicted SIRT1-Targeting MicroRNAs in the PFC

The following results describe expression changes in miRNAs that were bioinformatically predicted to target SIRT1.

4.4.1. miR-133a-3p

Our analysis showed that miR-133a-3p levels differed among groups ($F(3, 20) = 14.3$, $P < 0.0001$, $\eta^2 = 0.68$) (Figure 4A). The miR-133a-3p level in the METH-treated group was higher than that in the Saline + Veh group (1.56 ± 0.09 vs 1.02 ± 0.06 , $P < 0.001$). However, resveratrol administration before METH injection did not change miR-133a-3p levels compared with those in the METH group (1.53 ± 0.10 vs 1.56 ± 0.09 , $P = 0.98$). These findings indicate that METH significantly increased miR-133a-3p, whereas resveratrol had no effect on miR-133a-3p expression.

4.4.2. miR-22 - 3p

Our statistical analysis showed differences in miR-22 - 3p levels among experimental groups ($F(3, 20) = 53.88$, $P < 0.0001$, $\eta^2 = 0.89$) (Figure 4B). miR-22 - 3p levels were significantly increased in the METH + Veh group compared with the Saline + Veh group (2.28 ± 0.10 vs 1.02 ± 0.08 , $P < 0.0001$). Conversely, the METH + Resveratrol group showed reduced miR-22 - 3p levels compared with those in the METH + Veh group (1.79 ± 0.06 vs 2.28 ± 0.10 , $P < 0.01$). These data indicate that METH injection upregulated miR-22 - 3p and that resveratrol administration downregulated miR-22 - 3p.

4.4.3. miR-138 - 5p

Analysis showed differences in miR-138 - 5p levels among groups ($F(3, 20) = 28.23$, $P < 0.0001$, $\eta^2 = 0.80$) (Figure 4C). Rats that received METH and vehicle showed a significant increase in miR-138 - 5p levels compared with controls (2.33 ± 0.15 vs 1.02 ± 0.06 , $P < 0.0001$). Moreover, miR-138 - 5p levels were lower in the METH + Resveratrol group than in the METH + Veh group (1.75 ± 0.07 vs 2.30 ± 0.15 , $P < 0.05$). These data indicate that METH increased miR-138 - 5p levels; however, resveratrol administration reduced miR-138 expression in METH-injected rats.

4.4.4. miR-9 - 5p

The analysis revealed differences in miR-9 - 5p levels among groups ($F(3, 20) = 75.20$, $P < 0.0001$, $\eta^2 = 0.91$), indicating significant between-group changes (Figure 4D). Animals treated with METH and vehicle showed increased miR-9 - 5p expression compared with the Saline + Veh group (2.77 ± 0.09 vs 0.99 ± 0.05 , $P < 0.0001$). Moreover, resveratrol treatment in the METH + Resveratrol group decreased miR-9 - 5p levels compared with those in the METH + Veh group (2.19 ± 0.07 vs 2.77 ± 0.09 , $P < 0.01$).

4.5. Effect of Resveratrol on Cellular Morphology of the PFC

Histopathological examination of the PFC showed normal neuronal morphology in the Saline + Veh group and the Resveratrol group (Figure 5A and B). Neuronal damage and shrunken cell bodies were observed in the PFC of the METH + Veh group (Figure 5C). However, resveratrol treatment in the METH + Resveratrol group attenuated neuronal damage (Figure 5D). There was a significant difference in neuronal density among groups ($F(3, 20) = 9.07$, $P < 0.001$, $\eta^2 = 0.57$). Slides from the METH + Veh group showed decreased neuronal density compared with the Saline + Veh group (37.83 ± 2.35 vs 101.5 ± 3.47 , $P < 0.001$), whereas resveratrol administration in the METH + Resveratrol group increased neuronal density compared with that in the METH + Veh group (84.00 ± 4.17 vs 37.83 ± 2.35 , $P < 0.01$) (Figure 5E). Moreover, there was a significant difference in the number of damaged neurons among groups ($F(3, 20) = 57.30$, $P < 0.0001$, $\eta^2 = 0.89$). The number of damaged neurons increased in the METH + Veh group compared with the Saline + Veh group (11.17 ± 1.19 vs 40.33 ± 2.33 , $P < 0.0001$), and resveratrol administration in the METH + Resveratrol group decreased the number of damaged neurons compared with that in the METH + Veh group (21.33 ± 1.89 vs 40.33 ± 2.33 , $P < 0.0001$) (Figure 5F).

5. Discussion

Data from the current study revealed that METH damaged PFC tissue and decreased attention and working memory. Moreover, SIRT1 expression was reduced in the PFC following METH use. Resveratrol administration ameliorated the toxic effects of METH in the PFC and reduced METH-induced cognitive impairment. Increased SIRT1 protein contributed to the neuroprotective effects of resveratrol. In addition, SIRT1-related microRNAs, including miR-22 - 3p, miR-138 - 5p,




Figure 4. Effect of METH and resveratrol on the level of predicted microRNAs with a higher probability of preferential conservation related to SIRT1. The level of miR-133a-3p in the METH + Veh group was significantly higher than that in the Saline + Veh group. However, administration of resveratrol in the METH + Resveratrol group did not change the expression of miR-133a-3p compared with the METH + Veh group (A). The METH + Veh group showed enhanced miR-22-3p, miR-138-5p, and miR-9-5p levels compared with the Saline + Veh group. Conversely, the levels of miR-22-3p, miR-138-5p, and miR-9-5p were decreased in the METH + Resveratrol group compared with the METH + Veh group (B, C, and D). **** $P < 0.0001$ compared with the Saline + Veh group; *** $P < 0.001$ compared with the Saline + Veh group; ## $P < 0.01$ and # $P < 0.1$ compared with the METH + Veh group; $n = 6$ in each group.

and miR-9-5p, were altered during resveratrol-mediated neuroprotection.

Previously, reduced PFC volume and increased impulsive behaviors were observed in METH addicts (17). In addition, cognitive and electrophysiological studies

in human subjects have reported that METH consumption reduces attention, which correlates with alterations in prefrontal excitability (18). METH inhibited the proliferation of neural progenitor cells in the PFC. The sensitivity of PFC precursors to METH was associated with prominent neuronal inhibition in the




Figure 5. Histological evaluation of the PFC region using cresyl violet staining in different groups. Saline + Veh group (A), Saline + Resveratrol group (B), METH + Veh group (C), and METH + Resveratrol group (D). Neuronal density in the METH + Veh group was significantly reduced compared with the Saline + Veh group. Administration of resveratrol in the METH + Resveratrol group enhanced neuronal density compared with the METH + Veh group (E). The number of damaged neurons per field in the METH + Veh group increased compared with the Saline + Veh group. Administration of resveratrol in the METH + Resveratrol group decreased damaged neurons compared with the METH + Veh group (F). Arrows show damaged cells. Magnification, 400 $\times$; scale bar, 40 μ m. **** $P < 0.0001$ and *** $P < 0.001$ compared with the Saline + Veh group; #### $P < 0.0001$ and ## $P < 0.01$ compared with the METH + Veh group; $n = 6$ in each group.

PFC following METH use (19). In an experimental study, METH impaired autophagy and increased apoptosis and inflammation, along with morphological changes, enhanced astrogliosis, and decreased BDNF levels in the PFC in a rat model (20).

The results of our study showed that repeated METH use impaired cognition and reduced SIRT1 levels in the PFC of rats. METH dependency has been shown to be associated with neurocognitive impairments, including impairments in attention, learning, episodic memory, and working memory (21, 22). A functional imaging study of METH-dependent patients revealed that reduced working memory networks in the PFC underlie cognitive impairments in METH use disorder (23). Moreover, lower frontal cortex thickness was reported in METH abusers, and this reduction was significantly

associated with a longer duration of METH use (24). Komlao et al. reported that METH reduces stereotypic behavior and attentional-shifting task performance through increased endoplasmic reticulum stress profiles in the PFC (25). Notably, METH-induced attention deficits associated with reduced mitochondrial biogenesis in the PFC were reported in a rat model of METH abuse (10). Consistent with these clinical and laboratory findings, we observed decreased working memory and object-based attention after 14 days of METH administration in rats, accompanied by damage to PFC tissue.

Resveratrol is an effective natural phenolic compound that can reduce oxidative stress, ameliorate neuronal loss, and prevent cognitive impairment (26). Resveratrol has been reported to protect dopaminergic

neurons against METH-induced neurotoxicity by inhibiting oxidative stress and apoptosis. In addition, an *in vivo* study showed that resveratrol protected hippocampal neurons against METH-induced toxicity and improved animal performance in the novel object recognition behavioral test (27). The current study suggests that resveratrol can protect PFC tissue and improve working memory and attention against METH toxicity. Notably, examination of the PFC showed that resveratrol ameliorated METH-induced SIRT1 reduction. These findings suggest that resveratrol improves memory and attention and ameliorates PFC damage through a SIRT1-related mechanism.

Recently, several studies have reported that SIRT1 has diverse neuroprotective roles and that its overexpression ameliorates neurodegeneration (28, 29). SIRT1 upregulation in the hippocampus increased mitochondrial biogenesis and ameliorated memory impairment (30). In addition, decreased SIRT1 expression in the PFC of patients with Alzheimer disease has been reported and was related to cognitive decline and oxidative stress (28). Consistent with previous studies, we observed that SIRT1 downregulation due to METH consumption caused cognitive impairments in rats. In addition, increased SIRT1 expression in the PFC following resveratrol administration led to improved cognitive performance and protection of PFC neurons.

miRNAs are crucially involved in regulating the expression of many important genes and play key roles in several neurotoxic and neuroprotective pathways. We observed that the expression of SIRT1-related microRNAs, including miR-22 - 3p, miR-9 - 5p, and miR-138 - 5p, decreased following resveratrol treatment. Using a luciferase assay, miR-22 - 3p has been reported to target SIRT1 expression (31). In addition, nicotinamide decreased SIRT1 expression in periodontal ligament stem cells. Notably, miR-22 - 3p overexpression was found to be involved in nicotinamide-induced silencing of SIRT1. Downregulation of miR-22 - 3p modulated the production of the inflammatory cytokines tumor necrosis factor α and interleukin 1 β through a SIRT1-dependent pathway (31). Resveratrol administration decreased miR-22 - 3p levels in muscle cells, which was associated with increased SIRT1 levels in these cells (32).

It was previously reported that chronic administration of METH increased miR-9 - 5p in the nucleus accumbens of rats (33). This miRNA is highly expressed in the vertebrate brain and is associated with various neurological diseases. miR-9 - 5p is upregulated during neurodegenerative processes in Parkinson disease, which is associated with decreased SIRT1 expression. Knockdown of miR-9 - 5p inhibits

neurodegeneration and Parkinson disease progression, as evidenced by suppression of apoptotic, inflammatory, and oxidative stress pathways (34). miR-9 - 5p increased in a rat model of cerebrovascular cognitive impairment, and suppressing this miRNA improved cognitive impairments (35). It has been confirmed that miR-138 - 5p interacts with the 3'-UTR of SIRT1 mRNA and consequently prevents SIRT1 mRNA translation (36). Enhanced miR-138 - 5p levels in the postmortem PFC and hippocampus correlate with working memory impairment in human subjects (37). Upregulation of miR-138 - 5p in the hippocampus reduced memory function in the Y-maze and Morris water maze and increased inflammation in the hippocampus (38).

miR-133a-3p has been proposed as a serum biomarker for METH addiction (39). In addition, overexpression of this miRNA in the central nervous system was associated with increased neuronal death and cognitive disorders (40). Consistent with previous studies, we observed that SIRT1-related microRNAs, including miR-22 - 3p, miR-9 - 5p, miR-138 - 5p, and miR-133a-3p, were upregulated in the PFC following repeated METH use, which induced damage to the PFC region and impaired working memory and attention. Notably, resveratrol administration before METH injection inhibited the upregulation of miR-22 - 3p, miR-9 - 5p, and miR-138 - 5p, in association with increased SIRT1 protein expression. Higher SIRT1 levels in the PFC were associated with reduced PFC damage and improved working memory and attention.

5.1. Limitations

The key limitation is that the dependence of the protective effects of resveratrol on SIRT1 and the involvement of miRNAs in this pathway could not be directly demonstrated in this study. Although our results indicate a strong association among resveratrol treatment, levels of SIRT1-related miRNAs, and SIRT1 protein in the PFC, the current experimental design emphasizes establishing these associations rather than confirming these interactions. Our study lacked direct functional experiments, such as SIRT1 inhibition or the use of miRNA inhibitors. In addition, direct validation of miRNA predictions through methods such as luciferase assays was not performed in this model. Therefore, our findings are more consistent with a mechanism associated with changes in SIRT1 and its miRNAs than with their causal roles in resveratrol-induced protection. Future studies are required to clarify the roles of SIRT1 and specific miRNAs in resveratrol-mediated neuroprotection. The sample size for molecular analyses was also relatively limited ($n = 6$),

which may reduce the statistical power to detect slight molecular changes. Finally, although randomization, predefined exclusion criteria, and blinded outcome assessment were addressed, some reporting details and bias-control procedures may have influenced the findings. Examining the results in female animals affected by the estrous cycle could yield different results. Furthermore, although the control group in this study received subcutaneous injection of saline solution and oral 0.5% carboxymethylcellulose, a group receiving only 0.5% carboxymethylcellulose could provide useful information on the possible effects of this carrier alone.

5.2. Conclusions

We reported that METH decreased SIRT1 mRNA and protein in the PFC. Increased levels of miR-22 - 3p, miR-9 - 5p, miR-138 - 5p, and miR-133a-3p could be related to SIRT1 downregulation due to METH toxicity. METH damaged the PFC and impaired working memory and attention in the Y-maze and object-based attention tests. Moreover, oral administration of resveratrol effectively ameliorated the neurotoxic effects of METH on PFC tissue and improved cognitive test performance for working memory and attention. Notably, resveratrol enhanced SIRT1 levels in the PFC and reduced miR-22 - 3p, miR-9 - 5p, and miR-138 - 5p levels. These results indicate that resveratrol may be a potent neuroprotective agent against cognitive impairment and neurotoxicity caused by METH abuse. Future research is essential to clarify the role of SIRT1-related miRNAs in the neuroprotective effects of resveratrol in the PFC.

Acknowledgements

The authors are grateful for the support of the Clinical Research Development Unit, Emam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences.

Footnotes

AI Use Disclosure: The authors declare that no generative AI tools were used in the creation of this article.

Authors' Contribution: S. K. R.: Data curation, software, and writing; M. A. D.: Conceptualization, methodology, and analysis and interpretation; D. D.: Validation; F. S.: Visualization; All authors have read and approved the manuscript.

Conflict of Interests Statement: The authors declare that they have no conflicts of interest.

Data Availability: Derived data supporting the findings of this study are available from the corresponding author on request.

Ethical Approval: All experimental procedures were according to the NIH Guide for Care and Use of Laboratory Animals and Ethical Guidelines of the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences with ethical code IRAJUMS.AEC.1404.061.

Funding/Support: This study was supported by Ahvaz Jundishapur University of Medical Sciences by grant number CMRC-0435.

References

- Ramli FF, Rejeki PS, Ibrahim NI, Abdullayeva G, Halim S. A mechanistic review on toxicity effects of methamphetamine. *International Journal of Medical Sciences*. 2025;22(3):482-507. [PubMed ID: 39898237]. [PubMed Central ID: PMC11783064]. <https://doi.org/10.7150/ijms.99159>.
- Hu YB, Deng X, Liu L, Cao CC, Su YW, Gao ZJ, et al. Distinct roles of excitatory and inhibitory neurons in the medial prefrontal cortex in the expression and reconsolidation of methamphetamine-associated memory in male mice. *Neuropsychopharmacology*. 2024;49(12):1827-1838. [PubMed ID: 38730034]. [PubMed Central ID: PMC11473735]. <https://doi.org/10.1038/s41386-024-01879-2>.
- Poorvii R, Mohamed IN, Yahaya MF, Azmi N, Lin TS, Mohamed RMP, et al. Cognitive effects of methamphetamine and amphetamine withdrawal in rodents: A systematic review. *Frontiers in Psychology*. 2026;17: 1729722. [PubMed ID: 41969881]. [PubMed Central ID: PMC13062301]. <https://doi.org/10.3389/fpsyg.2026.1729722>.
- Moraes DS, Moreira DC, Andrade JMO, Santos SHS. Sirtuins, brain and cognition: A review of resveratrol effects. *IBRO Reports*. 2020;9:46-51. [PubMed ID: 33336103]. [PubMed Central ID: PMC7733131]. <https://doi.org/10.1016/j.ibror.2020.06.004>.
- Talebi S, Khodaghali F, Bahaeddin Z, Ansari Dezfooli M, Zeinaddini-Meymand A, Berchi Kankam S, et al. Does hazelnut consumption affect brain health and function against neurodegenerative diseases? *Nutritional Neuroscience*. 2024;27(9):1008-24. [PubMed ID: 38151890]. <https://doi.org/10.1080/1028415X.2023.2296164>.
- Labban S, Alghamdi BS, Alshehri FS, Kurdi M. Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer's disease. *Behavioural Brain Research*. 2021;402: 113100. [PubMed ID: 33417994]. <https://doi.org/10.1016/j.bbr.2020.113100>.
- Yildizhan K, Çinar R, Naziroğlu M. The involvement of TRPM2 on the MPP+-induced oxidative neurotoxicity and apoptosis in hippocampal neurons from neonatal mice: Protective role of resveratrol. *Neurological Research*. 2022;44(7):636-44. [PubMed ID: 35019826]. <https://doi.org/10.1080/01616412.2022.2027644>.
- De Sousa RAL. Molecular crosstalk for longevity: Exercise and the AMPK/SIRT1/PGC-1 α /Irisin/BDNF axis. *Molecular Biology Reports*. 2026;53(1): 142. [PubMed ID: 41317217]. <https://doi.org/10.1007/s11033-025-11315-3>.
- Baek H, Park M, Lee HJ. Nobiletin ameliorates Alzheimer's disease pathology by reducing oxidative stress and neuroinflammation through the AMPK/SIRT1/PGC-1 α and PI3K/Akt-CREB-BDNF pathways in

- 5XFAD mice. *Biomedicines*. 2026;**14**(3):561. [PubMed ID: 41898208]. [PubMed Central ID: PMC13023540]. <https://doi.org/10.3390/biomedicines14030561>.
10. Rashidi SK, Dezfouli MA, Khodagholi F, Dadashpour M, Shabani AA. Protective effect of melatonin against methamphetamine-induced attention deficits through miR-181/SIRT1 axis in the prefrontal cortex. *Molecular Biology Reports*. 2024;**51**(1). 690. [PubMed ID: 38796575]. <https://doi.org/10.1007/s11033-024-09631-1>.
11. Mahaman YAR, Ye A, Zhang Y, Chen M, Huang F, Liu R, et al. MicroRNAs in methamphetamine: Addiction, neurotoxicity, and therapeutic potential. *MedComm-Future Medicine*. 2026;**5**(1). e70049. <https://doi.org/10.1002/mef2.70049>.
12. Iamjan SA, Veerasakul S, Reynolds GP, Thanoi S, Nudmamud-Thanoi S. Regional-specific changes in rat brain BDNF in a model of methamphetamine abuse. *Neuroscience Letters*. 2024;**836**. 137880. [PubMed ID: 38885757]. <https://doi.org/10.1016/j.neulet.2024.137880>.
13. Wei YD, Chen XX, Yang LJ, Gao XR, Xia QR, Qi CC, et al. Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice. *Neurochemistry International*. 2022;**159**. 105385. [PubMed ID: 35843421]. [PubMed Central ID: PMC10350857]. <https://doi.org/10.1016/j.neuint.2022.105385>.
14. Ma X, Sun Z, Han X, Li S, Jiang X, Chen S, et al. Neuroprotective effect of resveratrol via activation of Sirt1 signaling in a rat model of combined diabetes and Alzheimer's disease. *Frontiers in Neuroscience*. 2020;**13**. 1400. [PubMed ID: 32038127]. [PubMed Central ID: PMC6985467]. <https://doi.org/10.3389/fnins.2019.01400>.
15. Khodamoradi M, Allameh Y, Sarani M, Zarei SA, Faaliat S, Ghazvini H. Memantine mitigates methamphetamine-induced impairments in social and recognition memories in rats. *BMC Neuroscience*. 2025;**26**(1). 36. [PubMed ID: 40474066]. [PubMed Central ID: PMC12143046]. <https://doi.org/10.1186/s12868-025-00955-7>.
16. Pestana JE, Graham BM. The impact of estrous cycle on anxiety-like behaviour during unlearned fear tests in female rats and mice: A systematic review and meta-analysis. *Neuroscience & Biobehavioral Reviews*. 2024;**164**. 105789. [PubMed ID: 39002829]. <https://doi.org/10.1016/j.neubiorev.2024.105789>.
17. Huang S, Dai Y, Zhang C, Yang C, Huang Q, Hao W, et al. Higher impulsivity and lower grey matter volume in the bilateral prefrontal cortex in long-term abstinent individuals with severe methamphetamine use disorder. *Drug and Alcohol Dependence*. 2020;**212**. 108040. [PubMed ID: 32428790]. <https://doi.org/10.1016/j.drugalcdep.2020.108040>.
18. Chen T, Su H, Wang L, Li X, Wu Q, Zhong N, et al. Modulation of methamphetamine-related attention bias by intermittent theta-burst stimulation on left dorsolateral prefrontal cortex. *Frontiers in Cell and Developmental Biology*. 2021;**9**. 667476. [PubMed ID: 34414178]. [PubMed Central ID: PMC8370756]. <https://doi.org/10.3389/fcell.2021.667476>.
19. Kim A, Mandyam CD. Methamphetamine affects cell proliferation in the medial prefrontal cortex: A new niche for toxicity. *Pharmacology Biochemistry and Behavior*. 2014;**126**:90-6. [PubMed ID: 25260424]. [PubMed Central ID: PMC4253078]. <https://doi.org/10.1016/j.pbb.2014.09.012>.
20. Tehrani AM, Boroujeni ME, Aliaghaei A, Feizi MAH, Safaralizadeh R. Methamphetamine induces neurotoxicity-associated pathways and stereological changes in prefrontal cortex. *Neuroscience Letters*. 2019;**712**. 134478. [PubMed ID: 31491463]. <https://doi.org/10.1016/j.neulet.2019.134478>.
21. Bernheim A, See RE, Reichel CM. Chronic methamphetamine self-administration disrupts cortical control of cognition. *Neuroscience & Biobehavioral Reviews*. 2016;**69**:36-48. [PubMed ID: 27450578]. [PubMed Central ID: PMC5030184]. <https://doi.org/10.1016/j.neubiorev.2016.07.020>.
22. Čechová B, Šlamberová R. Methamphetamine, neurotransmitters and neurodevelopment. *Physiological Research*. 2021;**70**(Suppl 3):S301-S315. [PubMed ID: 35099249]. [PubMed Central ID: PMC8884400]. <https://doi.org/10.33549/physiolres.934821>.
23. Nestor LJ, Ghahremani DG, London ED. Reduced neural functional connectivity during working memory performance in methamphetamine use disorder. *Drug and Alcohol Dependence*. 2023;**243**. 109764. [PubMed ID: 36610253]. <https://doi.org/10.1016/j.drugalcdep.2023.109764>.
24. Blake L, Williams KC, Uhlmann AA, Temmingh H, Burger A, Stein DJ, et al. Subcortical volumes, frontal cortical thickness, and pro-inflammatory cytokines in schizophrenia versus methamphetamine-induced psychosis. *Brain Imaging and Behavior*. 2025;**19**(4):874-88. [PubMed ID: 40425916]. [PubMed Central ID: PMC12310862]. <https://doi.org/10.1007/s11682-025-01022-9>.
25. Komlao P, Kraiwattanapirom N, Promyo K, Hein ZM, Chetsawang B. Melatonin enhances the restoration of neurological impairments and cognitive deficits during drug withdrawal in methamphetamine-induced toxicity and endoplasmic reticulum stress in rats. *Neurotoxicology*. 2023;**99**:305-12. [PubMed ID: 37979660]. <https://doi.org/10.1016/j.neuro.2023.11.006>.
26. Terracina S, Petrella C, Francati S, Lucarelli M, Barbato C, Minni A, et al. Antioxidant intervention to improve cognition in the aging brain: The example of hydroxytyrosol and resveratrol. *International Journal of Molecular Sciences*. 2022;**23**(24):15674. [PubMed ID: 36555317]. [PubMed Central ID: PMC9778814]. <https://doi.org/10.3390/ijms232415674>.
27. Zeng Q, Xiong Q, Zhou M, Tian X, Yue K, Li Y, et al. Resveratrol attenuates methamphetamine-induced memory impairment via inhibition of oxidative stress and apoptosis in mice. *Journal of Food Biochemistry*. 2021;**45**(2). e13622. [PubMed ID: 33502009]. <https://doi.org/10.1111/jfbc.13622>.
28. Cao K, Dong YT, Xiang J, Xu Y, Hong W, Song H, et al. Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease. *Journal of Clinical Pathology*. 2018;**71**(12):1090-9. [PubMed ID: 30185534]. <https://doi.org/10.1136/jclinpath-2018-205320>.
29. Zia A, Sahebdeh F, Farkhondeh T, Ashrafzadeh M, Zarrabi A, Hushmandi K, et al. A review study on the modulation of SIRT1 expression by miRNAs in aging and age-associated diseases. *International Journal of Biological Macromolecules*. 2021;**188**:52-61. [PubMed ID: 34364937]. <https://doi.org/10.1016/j.ijbiomac.2021.08.013>.
30. Ansari Dezfouli M, Zahmatkesh M, Farahmandfar M, Khodagholi F. Melatonin protective effect against amyloid β -induced neurotoxicity mediated by mitochondrial biogenesis; involvement of hippocampal Sirtuin-1 signaling pathway. *Physiology & Behavior*. 2019;**204**:65-75. [PubMed ID: 30769106]. <https://doi.org/10.1016/j.physbeh.2019.02.016>.
31. Zheng M, Guo J. Nicotinamide-induced silencing of SIRT1 by miR-22 - 3p increases periodontal ligament stem cell proliferation and differentiation. *Cell Biology International*. 2020;**44**(3):764-72. [PubMed ID: 31769563]. [PubMed Central ID: PMC7565205]. <https://doi.org/10.1002/cbin.11271>.
32. Wen W, Chen X, Huang Z, Chen D, Chen H, Luo Y, et al. Resveratrol regulates muscle fiber type conversion via miR-22 - 3p and AMPK/SIRT1/PGC-1 α pathway. *The Journal of Nutritional Biochemistry*. 2020;**77**. 108297. [PubMed ID: 32006744]. <https://doi.org/10.1016/j.jnutbio.2019.108297>.
33. Sim MS, Soga T, Pandey V, Wu YS, Parhar IS, Mohamed Z. MicroRNA expression signature of methamphetamine use and addiction in the rat nucleus accumbens. *Metabolic Brain Disease*. 2017;**32**(6):1767-83. [PubMed ID: 28681200]. <https://doi.org/10.1007/s11011-017-0061-x>.
34. Wang Z, Sun L, Jia K, Wang H, Wang X. miR-9 - 5p modulates the progression of Parkinson's disease by targeting SIRT1. *Neuroscience*

- Letters. 2019;**701**:226-33. [PubMed ID: [30826419](#)]. <https://doi.org/10.1016/j.neulet.2019.02.038>.
35. Wei N, Zheng K, Xue R, Ma SL, Ren HY, Huang HF, et al. Suppression of microRNA-9 - 5p rescues learning and memory in chronic cerebral hypoperfusion rats model. *Oncotarget*. 2017;**8**(64):107920-107931. [PubMed ID: [29296213](#)]. [PubMed Central ID: [PMC5746115](#)]. <https://doi.org/10.18632/oncotarget.22415>.
 36. Chen J, Qin R. MicroRNA-138 - 5p regulates the development of spinal cord injury by targeting SIRT1. *Molecular Medicine Reports*. 2020;**22**(1):328-36. [PubMed ID: [32319664](#)]. [PubMed Central ID: [PMC7248466](#)]. <https://doi.org/10.3892/mmr.2020.11071>.
 37. Schröder J, Ansaloni S, Schilling M, Liu T, Radke J, Jaedicke M, et al. MicroRNA-138 is a potential regulator of memory performance in humans. *Frontiers in Human Neuroscience*. 2014;**8**:501. [PubMed ID: [25071529](#)]. [PubMed Central ID: [PMC4093940](#)]. <https://doi.org/10.3389/fnhum.2014.00501>.
 38. Feng X, Hu J, Zhan F, Luo D, Hua F, Xu G. MicroRNA-138 - 5p regulates hippocampal neuroinflammation and cognitive impairment by NLRP3/caspase-1 signaling pathway in rats. *Journal of Inflammation Research*. 2021;**Volume 14**:1125-1143. [PubMed ID: [33814920](#)]. [PubMed Central ID: [PMC8009546](#)]. <https://doi.org/10.2147/JIR.S304461>.
 39. Li HC, Lin YB, Li C, Luo CH, Zhou YT, Ou JY, et al. Expression of microRNAs in the serum exosomes of methamphetamine-dependent rats vs. ketamine-dependent rats. *Experimental and Therapeutic Medicine*. 2018;**15**(4). 8025062. [PubMed ID: [29636786](#)]. [PubMed Central ID: [PMC5832017](#)]. <https://doi.org/10.1155/2018/8025062>.
 40. Luo M, Yi Y, Huang S, Dai S, Xie L, Liu K, et al. Gestational dexamethasone exposure impacts hippocampal excitatory synaptic transmission and learning and memory function with transgenerational effects. *Acta Pharmaceutica Sinica B*. 2023;**13**(9):3708-27. [PubMed ID: [37719378](#)]. [PubMed Central ID: [PMC10501875](#)]. <https://doi.org/10.1016/j.apsb.2023.05.013>.